Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
67Cu-SARTATE in recurrent or progressive meningioma
ACTRN12618000309280Phase 2Terminated
- Sponsor
- Clarity Pharmaceuticals
- Start
- Jul 2018
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of 67Cu-SARTATE in meningioma, sponsored by Clarity Pharmaceuticals. Primary endpoint: Safety and tolerability of multiple doses of 67Cu-SARTATE. Started Jul 2018; status: terminated.
02
Drugs
67Cu-SARTATE
03
Conditions
meningioma
Beyond the preview
Go deeper on ACTRN12618000309280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12618000309280.